A critical and often overlooked factor in managing hyperglycemia is hydration. Volume depletion from drug-induced diarrhea impairs the kidneys' ability to excrete glucose. This traps sugar in the body, creating a vicious cycle that dramatically elevates blood glucose levels.

While known for weight loss, GLP-1 agonists are also highly effective for managing hyperglycemia from both steroids and PI3K inhibitors. Using low or "micro" doses can be very helpful in cancer patients, providing glucose control while minimizing GI side effects like nausea.

Advances in drug design mean newer PI3K inhibitors are more targeted, resulting in significantly less off-target toxicity. For example, some investigational agents have a hyperglycemia risk under 15%, a substantial improvement over earlier drugs, making them easier to manage clinically.

Many clinicians mistakenly believe insulin's main role is blood glucose control. In reality, it's a master hormone signaling every cell—from brain to bone—to store energy. This function is so powerful it can slow the body's overall metabolic rate to prioritize energy storage.

On-body glucose monitors give oncologists a richer understanding of a patient's glucose control, including 24-hour trends, time-in-range, and an A1c equivalent (GMI). This real-time data is critical for managing hyperglycemia from targeted therapies, offering more insight than periodic fasting tests.

A patient with normal baseline glucose on an AKT inhibitor can experience a sudden, severe spike in blood sugar when they get sick (e.g., fever, infection). The illness acts as a physiological stressor, creating a "perfect storm" that demands immediate attention and patient education.

Many chronic illnesses, including high blood pressure, cancer, and cognitive decline, are not separate issues but symptoms of a single underlying problem: chronically elevated insulin levels. This metabolic “trash” accumulates over years, making the body a breeding ground for disease.

Oncologists typically initiate metformin for drug-induced hyperglycemia but are hesitant to manage more complex regimens. They prefer collaborating with endocrinologists who can navigate different drugs, dosages, and interactions, especially for complex oncology patients where frequent follow-up is needed.

Testing for PI3K/AKT alterations at the initial diagnosis of metastatic disease, rather than waiting for progression, provides a crucial window of time. This allows clinicians to implement proactive dietary and medical strategies to mitigate future side effects like hyperglycemia before the targeted therapy is even started.